ArticleJACC. Case reports2025
Contemporary Management of Severe Carcinoid Heart Disease.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarcinoid heart disease (CHD), despite its rarity, is a serious complication of carcinoid syndrome (CS). Approximately 50% of patients with CS will develop CHD during the course of their disease. It predominantly affects the right-sided heart valves, leading to valve defect and right heart failure. In patients with advanced functional neuroendocrine tumors, diagnosing and managing CHD remains a challenge. CASE SUMMARY: A 71-year-old male with a metastatic midgut neuroendocrine tumor and CS presented with worsening right heart failure. Despite initiating treatment appropriately, he deteriorated and ultimately died, highlighting the difficulty of CHD management in advanced cases. REVIEW SUMMARY: Early detection and prompt management of CS are vital to prevent the progression to CHD. Therefore, a carefully planned sequential management approach should be developed for a generalized adaptation. Multidisciplinary care is vital, and new percutaneous interventions could provide promising options for high-risk patients. TAKE-HOME MESSAGE: Routine screening of CHD in NET patients, timely intervention, and specialized multidisciplinary management are vital for improving outcomes in CHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.